Galecto's GB0139 Shows Favorable Safety In COVID-19 Patients, But Plans To Focus On Fibrosis, Cancer Programs
Corbus In-Licenses Two Anti-Integrin Antibodies Targeting Cancer, Fibrotic Diseases Settings
Liminal BioSciences Stock Falls on Scrapping Further Development of Fezagepras
Arrowhead's ARO-AAT Treatment Associated With Improved Fibrosis In Patients With Alpha-1 Liver Disease